Alcon to Buy Lensar in Deal Worth Up to $430M

Dow Jones

03-24

By Dean Seal

Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million.

The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027.

The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering.

The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders.

Shares of Lensar were halted at $14.57 in premarket trading.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

March 24, 2025 08:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2521740761"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521740761\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521740761?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521740761","market":"sg","top_or_hot":-1,"title":"Alcon to Buy Lensar in Deal Worth Up to $430M","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million. \n</p>\n<p>\n  The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027. \n</p>\n<p>\n  The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering. \n</p>\n<p>\n  The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders. \n</p>\n<p>\n  Shares of Lensar were halted at $14.57 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon to Buy Lensar in Deal Worth Up to $430M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon to Buy Lensar in Deal Worth Up to $430M\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-24 20:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million. \n</p>\n<p>\n  The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027. \n</p>\n<p>\n  The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering. \n</p>\n<p>\n  The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders. \n</p>\n<p>\n  Shares of Lensar were halted at $14.57 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"醫療保健用品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521740761","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521740761","pubTimestamp":1742818860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million.The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027.The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering.The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders.Shares of Lensar were halted at $14.57 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4082":"医疗保健设备","ALC":"爱尔康","LNSR":"LENSAR Inc","BK4534":"瑞士信贷持仓","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC"},"translate_title":"爱尔康将以高达4.3亿美元的价格收购Lensar","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9,"LNSR":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million. \n\n\n  The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027. \n\n\n  The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering. \n\n\n  The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders. \n\n\n  Shares of Lensar were halted at $14.57 in premarket trading. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 08:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}